Moleculin Cash And Short Term Investments from 2010 to 2024
| MBRX Stock | USD 2.62 0.03 1.13% |
Cash And Short Term Investments | First Reported 2015-09-30 | Previous Quarter 10.8 M | Current Value 9.4 M | Quarterly Volatility 24.7 M |
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
Moleculin | Cash And Short Term Investments |
Latest Moleculin Biotech's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Moleculin Biotech over the last few years. Short Term Investments is an account in the current assets section of Moleculin Biotech balance sheet. This account contains Moleculin Biotech investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Moleculin Biotech fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Moleculin Biotech's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Moleculin Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 13,729,601 | |
| Geometric Mean | 1,268,936 | |
| Coefficient Of Variation | 145.66 | |
| Mean Deviation | 14,204,966 | |
| Median | 7,134,000 | |
| Standard Deviation | 19,998,456 | |
| Sample Variance | 399.9T | |
| Range | 70.9M | |
| R-Value | 0.69 | |
| Mean Square Error | 224.7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 3,092,479 | |
| Total Sum of Squares | 5599.1T |
Moleculin Cash And Short Term Investments History
About Moleculin Biotech Financial Statements
Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 23.6 M | 22.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.